News
Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML
Overview
First time this CD83-targeting approach has been assessed in patients.
Primary goal is to study the safety of the target and the CAR T cells.
Research shows this therapy holds promise for treating AML and preventing GVHD.
In This Article
Roswell Park Comprehensive Cancer Center has launched an exclusive phase 1 clinical trial of a new chimeric antigen receptor (CAR) T-cell therapy for patients whose acute myeloid leukemia (AML) has relapsed or persisted despite earlier treatment. Developed at Roswell Park, this novel immunotherapy targets the CD83 antigen found on leukemia cells. The new strategy holds promise as a treatment for people whose leukemia returns following hematopoietic stem cell transplant — a group of people currently not eligible for other CAR T-cell clinical trials.
The Big Picture
This first-of-its-kind clinical trial of a therapy never before available to patients is made possible by generous donations to the Roswell Park Alliance Foundation and The 11 Day Power Play.
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. The Roswell Park team of 4,000+ makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Rated “Exceptional” by the National Cancer Institute, Roswell Park, founded in 1898, was one of the first NCI-designated comprehensive cancer centers in the country and remains the only one in Upstate New York.
